Press release article from our research archive:

ViaCell Announces Clinical Hold Formalizing Suspension of Enrollment in CB001 Study.

-- Clinical Hold Not in Response to New Events --

CAMBRIDGE, Mass., Sept. 21 /PRNewswire-FirstCall/ -- ViaCell, Inc. today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company's Phase I clinical trial evaluating CB001, an investigational cord blood stem cell product for hematopoietic stem cell transplantation in patients affected by a variety of cancers. The clinical hold is not in response to any new events in the study. The clinical hold formalizes an agreement between ViaCell and the FDA to suspend enrollment in the Phase I clinical trial.

As previously announced, ViaCell suspended enrollment in its CB001 Phase I ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!